Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational study to assess the Efficacy and Safety of Aprepitant for the prevention of nausea and vomiting associated with HEC/ MEC regimens

Trial Profile

Observational study to assess the Efficacy and Safety of Aprepitant for the prevention of nausea and vomiting associated with HEC/ MEC regimens

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Aprepitant (Primary)
  • Indications Nausea and vomiting
  • Focus Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals Ltd
  • Most Recent Events

    • 19 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top